Alloy Therapeutics, Inc.

We’re thrilled to announce that our Errik Anderson, CEO and Founder of Alloy Therapeutics, Inc. and General Partner 82VS will be speaking on the Innovation Panel at The 7th Annual Emerging Frontiers in Oncology. In this high-energy discussion, industry leaders will tackle the pressing question: Should stakeholders wait and see or take bold, strategic bets as we look ahead to 2025? This dynamic panel will feature thought leaders who are shaping the future of oncology: Errik Anderson - CEO and Founder, Alloy Therapeutics, Inc., General Partner, 82VS Alexis Borisy - Operating Chairman, Curie.Bio Irina Margine, Ph.D., PhD - Biotech Sector Lead, Wellington Management Jean-Francois Formela, MD - Partner, Atlas Ventures Keith Flaherty, MD - Professor, Mass General Hospital; Co-founder Loxo Oncology, Scorpion Therapeutics Joseph Pearlberg, MD PhD, MD, PhD - VP of Scientific Affairs, Deerfield Management Moderator: Prashant Girinath, PhD - Shareholder, Greenberg Traurig, LLP Join us May 22nd, 1–8 PM | MassBio | Catalyst Reception Learn more and register here : https://lnkd.in/gCfAcBX

We’re excited to partner with Multiomic Health to develop first-in-class, renal tissue-targeting therapies. By combining MultiOmic’s AI-enabled discovery platform with Alloy’s bispecific antibody and genetic medicine technologies, we aim to deliver safer, more effective precision treatments. This collaboration builds on our ecosystems growing momentum and shared commitment to advancing innovative medicines for patients. #makemedicinetogether #maythebestdrugwin

We are excited to see everyone at the #TCRSummit this week in Boston! Come learn from our expert, Dongxing Zha on April 2nd, as he will be presenting and sharing how to target pHLA for solid tumors using #KeywayTCR workflow for #TCRmimic discovery. While you are at the conference, swing by our booth to chat with the team, Scott McMenemy and Eugene Mironets, and explore more ways to accelerate your antibody-based therapeutic pipeline. #antibodydiscover #makemedicinetogether #maythebestdrugwin

Alloy Therapeutics, Inc. CEO and Founder Errik Anderson had the pleasure of speaking with BiotechTV’s Brad Loncar for an interview at our R&D Day earlier this week. The two discussed the latest developments regarding several of Alloy’s core modalities, including bispecifics, TCR mimics, and genetic medicines – they also touched on their newly discovered cross-town high school sports rivalry. https://lnkd.in/g6p8HE32 #makemedicinetogether #AlloyRnDDay #maythebestdrugwin

In this weeks Biotech Leader Spotlight we are recognizing Ugur Eskiocak, CEO of Voro Therapeutics! Check out his interview: Dr. Ugur Eskiocak is a #cancer #biologist and #biotech entrepreneur with extensive expertise in immuno-oncology, drug development, and translational sciences. He is the CEO & Co-Founder of Voro Therapeutics, where he leads the development of tumor-activated multi-specific antibodies (PrimeBody) to enhance cancer #immunotherapy. Previously, he was an Entrepreneur in Residence at Alloy Therapeutics, Inc., supporting biotech startups and advancing drug discovery. His industry experience includes leadership roles at Janux Therapeutics, Takeda, Xilio Therapeutics, Inc., and Compass Therapeutics Inc., where he directed translational and in vivo #pharmacology programs, contributing to IND-enabling studies and Phase 1 clinical trials. Dr. Eskiocak began his career in academia, conducting postdoctoral research at UT Southwestern Medical Center, where his work on #melanoma metastasis led to a Phase 1b clinical trial. He earned his Ph.D. in Cancer Biology from UT Southwestern and holds a Master’s and Bachelor’s degree in Molecular Biology and Genetics from Orta Doğu Teknik Üniversitesi / Middle East Technical University. Check out www.partnology.com for more biotech leader spotlights! #biotech #biopharma #clinicaldevelopment #drugdevelopment #biotechleaders #biotechexecutives #therapeutics #biotechnology

The Wheeler Bio, Inc. team is excited to announce the close of our latest series of funding to support the expansion of our capabilities here in OKC! With a laser focus on bringing success to our client's programs through our high-science, customer-centered approach, Wheeler is poised and primed to further our mission to change the CDMO landscape in favor of drug innovators and bring more therapies to patients in need. As we grow with our clients and support them throughout their discovery to commercial journey, Wheeler and our partners are more focused than ever on accelerating our client's lifesaving programs. This achievement would not be possible without our lead investors at Alloy Therapeutics, Inc., and Echo as well as our new partners at Mitsubishi Corporation, Russell Westbrook Enterprises, and Germin8 Ventures. Thank you all for your enthusiasm and support. This is only the beginning! #CDMO #Investment #Pharma #Biologics #PR

Congrats to Dren Bio, Inc.! Thrilled to see our partner’s innovation recognized as Sanofi acquires their bispecific myeloid cell engager for deep B-cell depletion.

Mark your calendars for the 7th Annual Emerging Frontiers in Oncology on May 22, 2025 from 1-8pm ET at MassBio in Cambridge, MA! Alloy Therapeutics, Inc. and 82VS are proud to support this important event, focused on the 2025 theme - Investing in Oncology: Aligning Stakeholders Amid Shifting Perspectives. Join us as we bring together leaders in #biotech and #oncology innovation to drive meaningful discussions and advancements in the field.   As part of the event, Alloy's CEO, Errik Anderson will join a panel to discuss "The Optimal Approach for 2025: Watch & Wait vs. Strategic Bets." Explore the full agenda and register here: https://lnkd.in/gCfAcBX

Update: Announcing the Agenda & Speakers for Alloy Therapeutics’ R&D Day! We’re thrilled to unveil the agenda and speaker lineup for Alloy Therapeutics’ R&D Day, where we’ll showcase groundbreaking advancements in biologics discovery. This event will highlight cutting-edge innovations—and how collaborations across the industry are accelerating therapeutic breakthroughs. 📅 Date: Tuesday, March 25th from 3-7pm 📍 Location: In-person at MassBio Hub in Cambridge, Ma Agenda: 1️⃣ Innovating Together: A Pfizer Collaboration in Developing the Common Light Chain Mouse for Therapeutic Discovery, Matthew Holsti, Pfizer 2️⃣ Case Study Showcase: Applying Alloy's Platforms for Bispecific Discovery, Mike Schmidt, Alloy Therapeutics 3️⃣ Looking Ahead: Advancing Drug Delivery with Antibody-Oligonucleotide Conjugates, Carlos Loya, 82VS 4️⃣ Panel Discussion: Enabling the Next Generation of Bispecifics, Conjugates, and Novel Biologics, Heather Schwoebel, Alloy Therapeutics; Morris Rosenberg, MRBC; Bryan Glaser, Invenra This is a must-attend event for scientists, biotech innovators, and partners to explore the latest in biologics discovery and collaborate on the future of therapeutic innovation. Register and secure your spot today 👉 https://lnkd.in/e74BbGgW

Looking forward to connecting at #Nextgenbiomed in London next week! Join us on March 14th as our SVP of Drug Development, Kent Bondensgaard, presents on #Bispecifics discovery. Stop by Booth 12 to meet our team (Scott McMenemy and Eugene Mironets) and learn how we can help fast-track your antibody-based therapeutic pipeline. See you there! #makemedicinetogether #maythebestdrugwin #antibodydiscovery